Innate Pharma, S.A. - רווח נקי למניה בארבעת הרבעונים האחרונים IPHA

Innate Pharma S.A. (IPHA) integrates environmental standards and bioethics into the development of anti-tumor antibodies. This price chart confirms the EPS dynamics, which currently stand at 1.20. The business generates revenue through the licensing of innovations, receiving long-term royalties from pharma behemoths. Research stability is supported by streamlined air delivery of biomaterials to global centers, ensuring the precision and continuity of all scientific processes.

Analyzing the TTM annual net income per share growth trend, we assess the status of Innate Pharma S.A. (IPHA) as a French oncology biotech. This indicator measures profit dynamics over 12 months, excluding one-time write-offs to identify the actual fundamental margin of safety. The gap between GAAP and adjusted data determines the risk of inflated investor expectations. For the company's academic culture, such transparency confirms the effectiveness of grant programs and the resilience of its scientific mission.